NO20051351L - Genterapi for kritisk iskemi i lemmer med villtype eller mutante eNOS - Google Patents

Genterapi for kritisk iskemi i lemmer med villtype eller mutante eNOS

Info

Publication number
NO20051351L
NO20051351L NO20051351A NO20051351A NO20051351L NO 20051351 L NO20051351 L NO 20051351L NO 20051351 A NO20051351 A NO 20051351A NO 20051351 A NO20051351 A NO 20051351A NO 20051351 L NO20051351 L NO 20051351L
Authority
NO
Norway
Prior art keywords
enos
polypeptides
wild
limbs
type
Prior art date
Application number
NO20051351A
Other languages
English (en)
Norwegian (no)
Inventor
Katalin Kauser
Gabor Rubanyi
William P Dole
Hu Sheng Qian
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20051351L publication Critical patent/NO20051351L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
    • C12N9/0075—Nitric-oxide synthase (1.14.13.39)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
NO20051351A 2002-08-16 2005-03-15 Genterapi for kritisk iskemi i lemmer med villtype eller mutante eNOS NO20051351L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40363702P 2002-08-16 2002-08-16
PCT/US2003/025626 WO2004016761A2 (en) 2002-08-16 2003-08-15 Gene therapy for critical limb ischemia with wild type or mutant enos

Publications (1)

Publication Number Publication Date
NO20051351L true NO20051351L (no) 2005-04-28

Family

ID=31888259

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051351A NO20051351L (no) 2002-08-16 2005-03-15 Genterapi for kritisk iskemi i lemmer med villtype eller mutante eNOS

Country Status (15)

Country Link
US (1) US20040120930A1 (enExample)
EP (1) EP1536689A4 (enExample)
JP (1) JP2005539031A (enExample)
KR (1) KR20050042162A (enExample)
CN (2) CN101391105A (enExample)
AU (1) AU2003263844A1 (enExample)
BR (1) BR0313515A (enExample)
CA (1) CA2494845A1 (enExample)
IL (1) IL166362A0 (enExample)
MX (1) MXPA05001763A (enExample)
NO (1) NO20051351L (enExample)
PL (1) PL375446A1 (enExample)
RU (1) RU2005107414A (enExample)
WO (1) WO2004016761A2 (enExample)
ZA (1) ZA200502181B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150359862A1 (en) * 2013-01-30 2015-12-17 Board Of Regents Of The University Of Nebraska Compositions and Methods for Treating Complications Associated with Diabetes
CA3025146A1 (en) * 2016-04-29 2017-11-02 Inovio Pharmaceuticals, Inc. The in vivo use of chondroitinase and/or hyaluronidase to enhance delivery of an agent
CN105944243A (zh) * 2016-05-12 2016-09-21 段俊丽 一种eNOS表达与活化的调控装置及周围动脉疾病的治疗装置
IL270388B2 (en) * 2017-05-02 2024-03-01 Univ Miami A method for treating ischemic tissue
CN107802826B (zh) * 2017-10-26 2020-02-18 首都医科大学宣武医院 eNOS突变体在促进血管生成中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002506008A (ja) * 1998-03-09 2002-02-26 セント エリザベス メディカル センター 血管新生を調整するための組成物及び方法
EP1016726A1 (en) * 1998-12-30 2000-07-05 Introgene B.V. Gene therapy to promote angiogenesis
SK14692001A3 (sk) * 1999-04-16 2002-09-10 Yale University Izolovaná molekula nukleovej kyseliny, izolovaný NOS polypeptid, spôsob stimulácie, spôsob liečby, spôsob identifikácie a nehumánne transgénne zviera

Also Published As

Publication number Publication date
EP1536689A2 (en) 2005-06-08
PL375446A1 (en) 2005-11-28
MXPA05001763A (es) 2005-08-19
EP1536689A4 (en) 2006-09-06
CA2494845A1 (en) 2004-02-26
BR0313515A (pt) 2005-10-18
ZA200502181B (en) 2006-09-27
CN1688197A (zh) 2005-10-26
WO2004016761A3 (en) 2005-03-17
CN101391105A (zh) 2009-03-25
CN100408101C (zh) 2008-08-06
RU2005107414A (ru) 2006-01-27
KR20050042162A (ko) 2005-05-04
US20040120930A1 (en) 2004-06-24
IL166362A0 (en) 2006-01-16
JP2005539031A (ja) 2005-12-22
AU2003263844A1 (en) 2004-03-03
WO2004016761A2 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
Samuk et al. Gene flow and selection interact to promote adaptive divergence in regions of low recombination
Paetkau et al. Genetic assignment methods for the direct, real‐time estimation of migration rate: a simulation‐based exploration of accuracy and power
David et al. Protein–protein interaction sites are hot spots for disease‐associated nonsynonymous SNPs
Dziedzic et al. Heritable variation in bleaching responses and its functional genomic basis in reef‐building corals (Orbicella faveolata)
Valente et al. DYT13, a novel primary torsion dystonia locus, maps to chromosome 1p36. 13–36.32 in an Italian family with cranial‐cervical or upper limb onset
Tsuchiya et al. Association of the calpain-10 gene with type 2 diabetes in Europeans: results of pooled and meta-analyses
Burchard et al. The importance of race and ethnic background in biomedical research and clinical practice
Rees et al. Understanding the evolution of human pigmentation: recent contributions from population genetics
Reconditi et al. Sarcomere‐length dependence of myosin filament structure in skeletal muscle fibres of the frog
NO20051351L (no) Genterapi for kritisk iskemi i lemmer med villtype eller mutante eNOS
Lopez et al. The interplay between natural selection and susceptibility to melanoma on allele 374F of SLC45A2 gene in a South European population
Poustka et al. On the origin of the chordate central nervous system: expression of onecut in the sea urchin embryo
Hughes et al. Parallel selection on TRPV6 in human populations
Ayyadevara et al. Lifespan extension in hypomorphic daf‐2 mutants of Caenorhabditis elegans is partially mediated by glutathione transferase CeGSTP2‐2
DK1590467T3 (da) Anvendelse af regulatoriske sekvenser til specifik, transient ekspression i neuronalt bestemte celler
Thompson et al. Rapid evolution of a voltage-gated sodium channel gene in a lineage of electric fish leads to a persistent sodium current
Tang et al. Joint testing of genotype and ancestry association in admixed families
Chen et al. What does the distribution of fitness effects of new mutations reflect? Insights from plants
Miller et al. Modeling incomplete penetrance in long QT syndrome type 3 through ion channel heterogeneity: an in silico population study
Carleton et al. Rod and cone opsin families differ in spectral tuning domains but not signal transducing domains as judged by saturated evolutionary trace analysis
Jons et al. Mutations in Conserved Amino Acids in the KCNQ1 Channel and Risk of Cardiac Events in Type‐1 Long‐QT Syndrome
Pimsler et al. Population genomics reveals a candidate gene involved in bumble bee pigmentation
Dieringer et al. Population structure in African Drosophila melanogaster revealed by microsatellite analysis
Hogner et al. Increased divergence but reduced variation on the Z chromosome relative to autosomes in Ficedula flycatchers: differential introgression or the faster‐Z effect?
Papke et al. Diversity of bacteriorhodopsins in different hypersaline waters from a single Spanish saltern

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application